FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
The IND application supports the next phase of development of SBO-154
SPARC to receive 55% equity in Tiller Therapeutics
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Subscribe To Our Newsletter & Stay Updated
